Board of Directors
Biogen Idec Phase III Clinical Trial "Empower"
An interview with Dr. Doug Kerr on the design and purpose of the dexpramipexole trial
Robert A. Goldstein
Doug Kerr, M.D., Ph.D. is a Medical Director in Experimental Neurology at Biogen Idec and the lead on their newly launched Phase III clinical trial in ALS. During this 20 minute interview, Kerr walks us through how Biogen Idec got to this point, how it designed the trial and what patients can expect from the trial in the clinic. The trial began enrolling in April 2011 and has a goal of 804 patients enrolled through 83 locations in North America, Europe and Australia.
Find this useful?
Help us fund more science: